OncoLab plans to expand its business scope based on the diverse applicability of ANGel platform, developing treatments not only for triple-negative breast cancer but also for various diseases such as other solid tumors, immune disorders, and inflammatory diseases.
Research and Development Pipeline
Category
Type of Cancer
Candidate Substance
Cell
Animal Experimentation
GLP & IND
Phase 1 Clinical Trial
Pursuing
Licensing Out
of Open
Innovation-
Based
Platform(25)
ANGel PD-L1:CTLA4
Triple-Negative Breast Cancer
ANGel Optimization & Confirmation of Loaded Drus(21)
Efficacy, Survial Rate, MOA & Toxicity Evaluation Expected to be Completed(25)
Clinical Trials to be Conducted & Results Expected to be Obtained(26)
Immuno-oncology & Innune Cell Activation
Hormone Receptor-Positive Breast Cancer
ANGel Optimization & Confirmation of Loaded Drus(21)
Efficacy & Toxicity Evaluation Completed(22)
ANGel Undisclosed Target
Prostate Cancer
ANGel Optimization & Confirmation of Loaded Drus(21)
Efficacy & Toxicity Evaluation Ongoing(23)
Immuno-oncology & Cancer Microenvironment Regulation
Other Cancer Disease
ANGel Optimization & Confirmation of Loaded Drus(21)
Efficacy & Toxicity Evaluation Ongoing(23)
The triple-negative breast cancer pipeline aims to enter Phase 1 clinical trials within three years to confirm toxicity and efficacy, facilitating licensing out.
The goal of jointly developing ANGel platform through open innovation is to reduce costs and achieve early revenue within two years through a non-exclusive licensing out model.
The core value of OncoLab's roadmap is to expand the application models of ANGel platform and establish a virtuous cycle through technology transfer.
By utilizing OncoLab's ANGel platform, we aim to achieve low-cost and rapid clinical applications compared to new drug development, resulting in low risk and high returns.
Clinical Status and Future Plans for Triple-Negative Breast Cancer and Prostate Cancer Treatments
ANGel-TNBC01 (Triple-Negative Breast Cancer Treatment)
This is the first pipeline developed based on ANGel platform. Preclinical studies are currently complete, and we aim to enter Phase 1 clinical trials in Q4 2026.
ANGel-TNBC02 (Triple-Negative Breast Cancer Treatment)
This pipeline aims to maximize cancer treatment efficacy and broaden its applicability by obtaining additional clinical data from ANGel-TNBC01. We target Phase 1 clinical trials in Q4 2027.
ANGel-PSC01 (Prostate Cancer Treatment)
Based on the experience gained from developing treatments for triple-negative breast cancer, we are conducting research for developing prostate cancer treatment. We aim to enter Phase 1 clinical trials in Q4 2028.
ANGel-PSC02 (Prostate Cancer Treatment)
This pipeline aims to maximize cancer treatment efficacy and expand its applicability by obtaining additional clinical data from ANGel-PSC01. We target Phase 1 clinical trials in Q4 2029.
Contact Us
CompanyOncoLab Co., Ltd.
Tel02-788-7400
Fax02-788-7401
Emailkim@oncolab.co.kr
HQ194-25 Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do (Chungbuk Center for Creative Economy and Innovation)
Lab380 Dongsan-dong, Deogyang-gu, Goyang-si, Gyeonggi-do, B-842, (Hyundai Premier Campus)
OncoLaB Hiring Guide
OncoLab is continuously hiring talented individuals in the field of biotechnology. Those interested in applying are encouraged to submit their documents via email.
CompanyOncoLab Co., Ltd.
Open PositionsResearch Team Leader, Experimental Researcher, GLP and GMP Coordinator